Phase 3 Parkinson's Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Children under 18 years old who have been diagnosed with congenital hyperinsulinism (a condition where the body produces too much insulin).
- Children under 18 years old who have been diagnosed with neuroblastoma (a type of cancer that develops from nerve cells).
- Children under 18 years old, or adults aged 18 and over, with a known or suspected neuroendocrine tumour (a type of tumour that can develop in hormone-producing cells).
- Adults aged 18 and over with a known or suspected diagnosis of Parkinson's disease or Lewy body dementia.
- Children under 18 years old, or adults aged 18 and over, who have been diagnosed with a brain tumour.
Who may not be able to join:
- People for whom consent cannot be obtained.
- People who weigh more than 225 kg, due to the weight limit of the scanning equipment used in the trial.
- Adults who are unable to lie still and flat for 20 to 30 minutes during the scan.
- Children under 13 years old who are unable to lie still and flat for 20 to 30 minutes, and for whom sedation is not considered medically safe by a specialist children's anaesthetist.
- People who do not have a usable vein for an intravenous line (a small tube placed into a vein).
- People who have previously had their gallbladder surgically removed — this exclusion applies only to a specific part of the study involving abdominal scans (confirm with trial site).
- People who are pregnant.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jonathan Abele, MD, University of Alberta
Phone: 1-780-407-6907
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Minimum lesion detectibility (size); Assessment of bladder activity; Assessment of bladder activity artifact; Minimum lesion detectability (SUV)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.